Neuroregeneration Therapies for Neurodegeneration

Migration, Crosslink

📖

Neuroregeneration Therapies for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-neuroregeneration-ther

📖 Wiki Page

therapeutic2444 wordssynced 2026-04-02

Neuroregeneration Therapies for Neurodegeneration

Introduction

Neuroregeneration Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

Neuroregeneration Therapies for Neurodegeneration

Introduction

Neuroregeneration Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

Neuroregeneration therapies represent a transformative approach to treating neurodegenerative diseases by focusing on repairing, replacing, or regenerating damaged [neurons](/entities/neurons) and neural circuits. Unlike disease-modifying therapies that primarily target underlying pathology (such as [amyloid-beta](/proteins/amyloid-beta-protein) plaques or [tau](/proteins/tau) tangles), neuroregenerative approaches aim to restore lost neuronal function, rebuild neural networks, and promote recovery of cognitive and motor abilities.

This field encompasses multiple therapeutic strategies including cell replacement therapy, neurotrophic factor delivery, axonal regeneration promotion, and stimulation of endogenous neural stem cells.

<div class="infobox infobox-treatment">
<table>
<tr><th colspan="2">Neuroregeneration Therapies</th></tr>
<tr><td>Primary Goal</td><td>Restore neuronal function and connectivity</td></tr>
<tr><td>Key Approaches</td><td>Cell therapy, neurotrophic factors, axonal regeneration, endogenous repair</td></tr>
<tr><td>Target Diseases</td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), [Huntington's Disease](/diseases/huntington-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis)</td></tr>
<tr><td>Clinical Status</td><td>Multiple Phase 1/2 trials, some Phase 3</td></tr>
<tr><td>Leading Modalities</td><td>iPSC-derived neurons, GDNF delivery, anti-Nogo therapy</td></tr>
</table>
</div>

Mechanisms of Neural Repair

1. Endogenous Neurogenesis

The adult brain contains neural stem cells in two primary regions [@ming2011]:

Subventricular zone (SVZ): Lines the lateral ventricles, generates interneurons
Subgranular zone (SGZ): Within the dentate gyrus, generates granule cells

Therapeutic strategies to enhance endogenous neurogenesis:

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Exercise/Enrichment | Increases [BDNF](/proteins/bdnf-protein), hippocampal neurogenesis | Clinical |
| Growth factors | FGF2, EGF stimulate NSC proliferation | Preclinical |
| Small molecules | P7C3, PDE inhibitors enhance neurogenesis | Clinical trials |
| Modulators | Wnt agonists, Notch inhibitors | Research |

Challenges: Neurogenesis declines with age and is impaired in neurodegenerative diseases. Strategies must overcome this deficit while ensuring proper integration of new neurons.

2. Axonal Regeneration

Unlike the peripheral nervous system, CNS axons have limited regenerative capacity due to [@schwab2014]:

Intrinsic limitations:

Reduced expression of growth-associated genes
Declining protein synthesis capacity
Epigenetic repression of regeneration programs

Extrinsic inhibitors:

Nogo-A: Myelin-associated inhibitor, signals through NgR1
MAG: Myelin-associated glycoprotein
OMgp: Oligodendrocyte myelin glycoprotein
Chondroitin sulfate proteoglycans (CSPGs): Glial scar component

Therapeutic targets:

| Target | Approach | Status |
|--------|----------|--------|
| Nogo-A/NgR1 | Anti-Nogo antibodies, NgR1 decoys | Phase 2/3 (stroke, SCI) |
| RhoA/ROCK | Small molecule inhibitors | Clinical trials |
| PTEN deletion | Gene therapy to enhance growth | Preclinical |
| cAMP elevation | PDE4 inhibitors, forskolin | Clinical |
| KLF4/9 suppression | Transcriptional reprogramming | Research |

3. Synaptic Plasticity Enhancement

Restoring synaptic function is crucial for cognitive recovery [@poo2016]:

Approaches:

BDNF-TrkB agonists: Promote synaptic strengthening
AMPA receptor modulators: Enhance synaptic transmission
Synapse formation factors: Agrin, neuroligin/neurexin modulation
Rehabilitation protocols: Activity-dependent plasticity

4. Cell Replacement Therapy

Transplanting new neurons or progenitors to replace lost cells [@parmar2020]:

Fetal tissue: Historical approach, proof of principle
Embryonic stem cells (ESCs): Unlimited source, ethical concerns
Induced pluripotent stem cells (iPSCs): Patient-specific, avoids rejection
Direct lineage conversion: Transdifferentiation without pluripotency

Cell-Based Therapies

Dopamine Neuron Replacement for Parkinson's Disease

PD is the leading target for cell replacement therapy due to well-defined cell loss [@kriks2011]:

Fetal Dopamine Cell Transplantation

History: First trials in 1980s-1990s
Results: Some patients showed dramatic improvement; others had graft-induced dyskinesias
Lessons learned: Standardized protocols, patient selection critical
Current status: Renewed interest with improved protocols

iPSC-Derived Dopamine Neurons

Leading programs:

| Program | Source | Trial Phase | Key Features |
|---------|--------|-------------|--------------|
| CiRA (Kyoto) | Autologous iPSC | Phase 1/2 | First patient transplanted 2018 |
| BlueRock/Bayer | Allogeneic iPSC | Phase 1 | "Off-the-shelf" approach |
| Aspen Neuroscience | Autologous iPSC | Phase 1/2 | Patient-specific cells |
| Memory-GSK | Allogeneic iPSC | Phase 1 | Immunomodulation |

Manufacturing considerations:

Standardized differentiation protocols (floor-plate method)
Purification to remove undifferentiated cells
Quality control for identity, purity, potency
Cryopreservation for "off-the-shelf" use

Direct Lineage Conversion

Converting [astrocytes](/entities/astrocytes) to dopamine neurons in situ [@rivetti2017]:

Approach: Viral delivery of transcription factors (Ascl1, Lmx1a, Nurr1)
Advantage: Avoids transplantation, uses resident cells
Challenge: Efficiency, proper circuit integration
Status: Preclinical research

Medium Spiny Neuron Replacement for Huntington's Disease

HD involves selective loss of striatal medium spiny neurons (MSNs) [@rossignol2015]:

Approaches:

Fetal striatal tissue: Early trials showed survival but limited benefit
iPSC-derived MSNs: Differentiated using region-specific protocols
Neural progenitor cells: CXCL12-guided migration to striatum

Challenges:

Complex circuitry requires proper connectivity
Disease environment may be hostile to grafts
mHTT toxicity affects transplanted cells

Motor Neuron Replacement for ALS

ALS involves progressive motor neuron loss [@thomsen2014]:

Challenges unique to ALS:

Rapidly progressive disease limits time for integration
Glial dysfunction affects graft survival
Ongoing toxicity continues to damage grafts

Current approaches:

iPSC-derived motor neurons: Proof-of-concept in models
Stem cell-derived trophic support: MSC transplantation for neuroprotection
Gene-corrected autologous cells: For familial ALS with known mutations

Neurotrophic Factor Therapy

Overview of Key Neurotrophic Factors

| Factor | Primary Target | Disease Application | Delivery Challenge |
|--------|---------------|---------------------|-------------------|
| [GDNF](/proteins/gdnf-protein) | Dopamine neurons | PD | Requires intraparenchymal infusion |
| [BDNF](/proteins/bdnf-protein) | Cortical/hippocampal | AD, HD | Poor [BBB](/entities/blood-brain-barrier) penetration |
| [NGF](/proteins/ngf-protein) | Cholinergic neurons | AD | Painful side effects |
| [CNTF](/proteins/cntf-protein) | Motor neurons | ALS | Weight loss, toxicity |
| [NT-3](/proteins/nt-3-protein) | Proprioceptive neurons | SCI | Diffuse expression needed |

GDNF for Parkinson's Disease

GDNF supports survival and function of dopaminergic neurons [@barker2020]:

Delivery approaches:

Direct infusion: Convection-enhanced delivery (CED) to putamen

Results: Mixed; some showed benefit, others did not
Issues: Invasive, requires surgical implantation, limited distribution

Encapsulated cell therapy: Immunoisolated cells producing GDNF

Agent: NsG0202 (NsGene)
Status: Phase 1/2 completed, modest benefits

AAV-GDNF gene therapy: Viral delivery for sustained expression

Advantage: One-time treatment, widespread expression
Status: Preclinical development

GDNF mimetics: Small molecules activating Ret receptor

Advantage: Oral bioavailability
Challenge: Specificity, blood-brain barrier penetration

BDNF for Alzheimer's Disease

BDNF supports hippocampal and cortical neurons [@nagahara2011]:

Clinical challenges:

Rapid degradation in plasma
Poor blood-brain barrier penetration
Receptor (TrkB) downregulation in AD

Alternative approaches:

TrkB agonists: Small molecules (7,8-DHF, LM22A-4)
AAV-BDNF: Gene therapy for sustained delivery
Exercise programs: Endogenous BDNF enhancement
PDE4 inhibitors: Increase cAMP → CREB → BDNF transcription

NGF for Alzheimer's Disease

NGF supports basal forebrain cholinergic neurons [@tuszynski2015]:

AAV-NGF (CERE-110):

Mechanism: Gene therapy delivering NGF to basal forebrain
Trial results: Phase 1 showed safety; Phase 2 showed no cognitive benefit
Lessons: Dosing and targeting critical; degeneration may be too advanced

Axonal Regeneration Therapies

Anti-Nogo Therapy

Nogo-A is a major myelin-associated inhibitor of axonal regeneration [@lee2015]:

ATI-355 (Anti-Nogo-A Antibody)

Mechanism: Blocks Nogo-A, releases brake on axonal growth
Delivery: Intrathecal infusion
Trials: Phase 2/3 in stroke (completed), spinal cord injury
Results: Mixed; some functional improvement in stroke patients

NgR1 Decoy Receptor

Agent: AX2002 (soluble NgR1 fusion protein)
Mechanism: Sequesters Nogo-A, MAG, OMgp
Status: Preclinical/early clinical

RhoA/ROCK Inhibition

The RhoA-ROCK pathway mediates growth inhibition signals [@fournier2003]:

| Agent | Type | Status |
|-------|------|--------|
| Fasudil | ROCK inhibitor | Approved in Japan for stroke |
| Y-27632 | ROCK inhibitor | Preclinical |
| C3 transferase | RhoA inhibitor | Preclinical |
| Veritide | RhoA antagonist | Research |

PTEN Deletion

PTEN is a negative regulator of [mTOR](/entities/mtor) that limits axonal regeneration [@park2008]:

Approach: AAV-Cre mediated PTEN deletion in neurons
Effect: Robust axonal regeneration in optic nerve, spinal cord models
Challenge: Oncogenic potential of PTEN loss; requires careful targeting
Status: Research stage

Clinical Trial Landscape

Active Neuroregeneration Trials (2025)

| Trial | Modality | Disease | Phase | Agent |
|-------|----------|---------|-------|-------|
| TRANSEURO | Fetal dopamine cells | PD | Phase 2 | Fetal VM tissue |
| Kyoto iPSC | Autologous iPSC | PD | Phase 1/2 | iPS-dopamine |
| BlueRock | Allogeneic iPSC | PD | Phase 1 | Bemdaneprocel |
| STEMS-PD | MSC infusion | PD | Phase 2 | MSC |
| ASTRO | AAV-GDNF | PD | Phase 1 | AAV2-GDNF |
| Nogo-A Stroke | Anti-Nogo | Stroke | Phase 2 | ATI-355 |

Challenges and Future Directions

Key Challenges

| Challenge | Description | Potential Solutions |
|-----------|-------------|---------------------|
| Integration | New neurons must form correct connections | Activity-based training, guidance cues |
| Survival | Hostile disease environment | Anti-inflammatory co-therapies |
| Scalability | Manufacturing clinical-grade cells | Automated bioreactors, standardized protocols |
| Timing | When to intervene | Biomarker-guided treatment |
| Rejection | Immune response to allogeneic cells | HLA-matching, immunosuppression |

Emerging Technologies

Organoid transplantation: 3D brain organoids for complex circuitry

CRISPR-enhanced cells: Gene-corrected cells for genetic diseases

Biomaterial scaffolds: Guiding axonal growth and cell integration

Optogenetic control: Remote control of transplanted neuron activity

Combinatorial approaches: Cells + factors + rehabilitation

Personalized Medicine

Patient-specific iPSCs: Autologous cells avoiding rejection
Genetic correction: CRISPR-editing of disease mutations
Disease modeling: iPSC-derived neurons for drug screening
Biomarker guidance: [NfL](/proteins/nfl-protein), imaging to guide treatment timing

Summary

| Aspect | Key Points |
|--------|------------|
| Goal | Restore neuronal function and connectivity |
| Cell therapy | iPSC-derived neurons for PD, HD, ALS |
| Neurotrophic factors | GDNF, BDNF, NGF delivery via gene therapy or infusion |
| Axonal regeneration | Anti-Nogo, ROCK inhibitors, PTEN deletion |
| Leading indication | Parkinson's Disease (dopamine neuron replacement) |
| Clinical status | Multiple Phase 1/2 trials; Phase 3 in stroke/SCI |
| Key challenge | Circuit integration and functional recovery |

Background

The study of Neuroregeneration Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Advanced Regeneration Approaches

Gene Therapy for Neurotrophic Factor Delivery

AAV-GDNF (AAV2-GDNF)

| Property | Value |
|----------|-------|
| Approach | Adeno-associated virus delivery of GDNF |
| Mechanism | Continuous GDNF expression in striatum |
| Target | Parkinson's disease |

Clinical Status: Phase 1/2 trials showing safety; motor improvements observed

Rationale: GDNF promotes survival of dopaminergic neurons; AAV enables long-term expression

AAV-NRTN (CERE-120)

| Property | Value |
|----------|-------|
| Approach | AAV delivery of Neurturin |
| Mechanism | Retrograde transport to substantia nigra |
| Target | Parkinson's disease |

Clinical Status: Phase 1/2 completed; Phase 2b showed mixed results

Cell Replacement Therapy

Dopaminergic Neuron Transplantation

| Property | Value |
|----------|-------|
| Cell Source | Human embryonic stem cells, iPSCs |
| Target | Parkinson's disease |
| Approach | Replace lost dopaminergic neurons in substantia nigra |

Clinical Status: Multiple trials; embryonic stem cell-derived neurons in Phase 1/2

Cholinergic Neuron Replacement

| Property | Value |
|----------|-------|
| Cell Source | iPSC-derived cholinergic neurons |
| Target | Alzheimer's disease, basal forebrain degeneration |
| Approach | Replace cholinergic neurons for memory restoration |

Clinical Status: Preclinical; targeting clinical trials in 2025-2026

Axonal Regeneration

Anti-Nogo-A Antibody (GSK-1223249)

| Property | Value |
|----------|-------|
| Approach | Monoclonal antibody against Nogo-A |
| Mechanism | Block Nogo-mediated axonal growth inhibition |
| Target | Spinal cord injury, potentially ALS |

Clinical Status: Phase 1 completed; exploring neurodegenerative applications

PTEN Deletion

| Property | Value |
|----------|-------|
| Approach | Genetic or pharmacological [mTOR](/mechanisms/mtor-signaling-pathway) activation |
| Mechanism | Remove PTEN brake on axonal regeneration |
| Target | Promote optic nerve and spinal cord regeneration |

Clinical Status: Preclinical; gene therapy approaches in development

Functional Restoration

Deep Brain Stimulation (DBS) for Regeneration

| Property | Value |
|----------|-------|
| Approach | Network-level stimulation to restore function |
| Mechanism | Modulate neural circuits, promote plasticity |
| Target | Advanced PD, dystonia, OCD |

Clinical Status: FDA-approved; research on closed-loop adaptive DBS

Brain-Machine Interface (BMI) Integration

| Property | Value |
|----------|-------|
| Approach | Neural interfaces to bypass damaged circuits |
| Mechanism | Direct neural signaling to restore function |
| Target | Severe motor deficits |

Clinical Status: Rapidly advancing; clinical trials for motor restoration

Combinatorial Approaches

Cell Therapy + Gene Therapy

| Property | Value |
|----------|-------|
| Combination | iPSC-derived neurons + neurotrophic factor delivery |
| Mechanism | Enhanced survival and integration of transplanted cells |
| Target | PD, HD, ALS |

Rationale: Combining cell replacement with growth factor support improves graft survival and function

Rehabilitation + Regeneration

| Property | Value |
|----------|-------|
| Combination | Intensive rehabilitation + regenerative therapy |
| Mechanism | Activity-dependent plasticity enhanced by regeneration |
| Target | All neurodegenerative conditions |

Rationale: Physical therapy and cognitive training may synergize with biological regeneration

External Links

[ISSCR Guidelines for Stem Cell Research](https://www.isscr.org/guidelines)
[NIH Stem Cell Information](https://stemcells.nih.gov/)
[ClinicalTrials.gov - Neuroregeneration](https://clinicaltrials.gov/search?cond=neurodegenerative+disease&intr=neuroregeneration)
[Michael J. Fox Foundation - Cell Therapy](https://www.michaeljfox.org/)
[HD Stem Cell Consortium](https://www.hdsc.org/)

References

[Ming GL, Song H, Adult neurogenesis in the mammalian brain: significant answers and significant questions (2011)](https://doi.org/10.1016/j.neuron.2011.05.001)

[Schwab ME, Strittmatter SM, Nogo limits neural plasticity and recovery from CNS injury (2014)](https://doi.org/10.1016/j.conb.2014.03.007)

[Poo MM, et al, What is synaptic plasticity? Nat Rev Neurosci (2016)](https://doi.org/10.1038/nrn.2016.100)

[Parmar M, et al, How can hPSCs replace dopaminergic neurons in Parkinson's patients? Cell Stem Cell (2020)](https://doi.org/10.1016/j.stem.2019.12.003)

[Kriks S, et al, Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease (2011)](https://doi.org/10.1038/nature10648)

[Rivetti di Val Cervo P, et al, Induction of functional dopamine neurons from human astrocytes in vitro and in vivo (2017)](https://doi.org/10.1038/nbt.3835)

[Rossignol J, et al, Mesenchymal stem cell transplantation for Huntington's disease (2015)](https://doi.org/10.3727/096368915X687640)

[Thomsen GM, et al, Stem cell transplantation for ALS (2014)](https://doi.org/10.1007/s13311-014-0286-7)

[Barker RA, et al, GDNF and the treatment of Parkinson's disease (2020)](https://doi.org/10.1038/s41582-020-0334-2)

[Nagahara AH, Tuszynski MH, Potential therapeutic uses of BDNF in neurological and psychiatric disorders (2011)](https://doi.org/10.1038/nrd3366)

[Tuszynski MH, et al, Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer's disease (2015)](https://doi.org/10.1001/jamaneurol.2015.1807)

[Lee JK, et al, Nogo receptor antagonism promotes stroke recovery by enhancing synaptic plasticity (2015)](https://doi.org/10.1523/JNEUROSCI.3014-14.2015)

[Fournier AE, et al, Inhibition of Rho promotes axonal regeneration (2003)](https://doi.org/10.1523/JNEUROSCI.23-04-01416.2003)

[Park KK, et al, PTEN deletion enhances the regenerative ability of adult corticospinal neurons (2008)](https://doi.org/10.1038/nature06857)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Neuroregeneration Therapies for Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-neuroregeneration-therapies-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-neuroregeneration-therapies-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-992f729a088a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-neuroregeneration-therapies-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

575

Outgoing

726

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Neuroregeneration Therapies for Neurodegeneration

Neuroregeneration Therapies for Neurodegeneration

Introduction

Overview

Neuroregeneration Therapies for Neurodegeneration

Introduction

Overview

Mechanisms of Neural Repair

1. Endogenous Neurogenesis

2. Axonal Regeneration

3. Synaptic Plasticity Enhancement

4. Cell Replacement Therapy

Cell-Based Therapies

Dopamine Neuron Replacement for Parkinson's Disease

Fetal Dopamine Cell Transplantation

iPSC-Derived Dopamine Neurons

Direct Lineage Conversion

Medium Spiny Neuron Replacement for Huntington's Disease

Motor Neuron Replacement for ALS

Neurotrophic Factor Therapy

Overview of Key Neurotrophic Factors

GDNF for Parkinson's Disease

BDNF for Alzheimer's Disease

NGF for Alzheimer's Disease

Axonal Regeneration Therapies

Anti-Nogo Therapy

ATI-355 (Anti-Nogo-A Antibody)

NgR1 Decoy Receptor

RhoA/ROCK Inhibition

PTEN Deletion

Clinical Trial Landscape

Active Neuroregeneration Trials (2025)

Challenges and Future Directions

Key Challenges

Emerging Technologies

Personalized Medicine

Summary

Background

Advanced Regeneration Approaches

Gene Therapy for Neurotrophic Factor Delivery

AAV-GDNF (AAV2-GDNF)

AAV-NRTN (CERE-120)

Cell Replacement Therapy

Dopaminergic Neuron Transplantation

Cholinergic Neuron Replacement

Axonal Regeneration

Anti-Nogo-A Antibody (GSK-1223249)

PTEN Deletion

Functional Restoration

Deep Brain Stimulation (DBS) for Regeneration

Brain-Machine Interface (BMI) Integration

Combinatorial Approaches

Cell Therapy + Gene Therapy

Rehabilitation + Regeneration

See Also

External Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion